Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 288

The DOI matches its Crossref record.

Treatment of Schizophrenia With Long-Acting Injectable Risperidone: A 12-Month Open-Label Trial of the First Long-Acting Second-Generation Antipsychotic

Fleischhacker, W. Wolfgang, Eerdekens, Mariëlle, Karcher, Keith, Remington, Gary, Llorca, Pierre-Michel, Chrzanowski, Wlodzimierz, Martin, Stephen, Gefvert, Ola·2003·The Journal of Clinical Psychiatry

Abstract

BACKGROUND: The long-term safety and efficacy of long-acting injectable risperidone, the first long-acting second-generation antipsychotic, were evaluated in stable patients with schizophrenia. METHOD: After a 2-week run-in period during which patients with DSM-IV schizophrenia received flexible doses of 1 to 6 mg of oral risperidone, patients received injections of 25 mg, 50 mg, or 75 mg of long-acting risperidone every 2 weeks for 12 months. Severity of extrapyramidal symptoms was assessed with the Extrapyramidal Symptom Rating Scale (ESRS), and efficacy was assessed with the Positive and Negative Syndrome Scale (PANSS). This study was conducted from March 29, 1999 to July 19, 2000. RESULTS: The subjects were 615 patients with schizophrenia who received at least 1 injection of long-acting risperidone. The 12-month trial was completed by 65% of patients. Treatment was discontinued because of adverse events in 5% of patients. Extrapyramidal symptoms as adverse events were reported by 25% of the patients. Severity of extrapyramidal symptoms (according to ESRS scores) was low at baseline and decreased in each of the groups during the 12 months. The other most common adverse events were anxiety in 24%, insomnia in 21%, psychosis in 17%, and depression in 14% of the patients. Little pain was associated with the injections. Severity of symptoms of schizophrenia was improved in each group, with significant reductions in PANSS total scores (p <.01) and positive (p <.01) and negative (p <.001) factor scores. CONCLUSION: In terms of both safety and efficacy, symptomatically stable patients with schizophrenia benefit from being switched to long-acting injectable risperidone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4088/jcp.v64n1017

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 288

Metadata

Authors
Fleischhacker, W. W., Eerdekens, M., Karcher, K., Remington, G., Llorca, P.-M., Chrzanowski, W., Martin, S., & Gefvert, O.
Venue
The Journal of Clinical Psychiatry
Published
2003-10-15
Volume
64
Issue
10
Pages
1250-1257
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2020615571
Cited by
288
References
0
FWCI
17.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Schizophrenia With Long-Acting Injectable Risperidone: A 12-Month Open-Label Trial of the First Long-Acting Second-Generation Antipsychotic. https://app.cochat.ai/papers/10.4088/jcp.v64n1017
The paper
Fleischhacker, W. W., Eerdekens, M., Karcher, K., Remington, G., Llorca, P.-M., Chrzanowski, W., Martin, S., & Gefvert, O. (2003). Treatment of Schizophrenia With Long-Acting Injectable Risperidone: A 12-Month Open-Label Trial of the First Long-Acting Second-Generation Antipsychotic. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v64n1017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.